Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
Alex Azar, speaking in Uganda, told reporters that he and others are “very concerned” and urged Tanzania’s government to share laboratory results regarding the case. The Ebola outbreak in neighboring Congo has become the second-deadliest in history, with confirmed cases now exceeding 3,000. Azar said efforts were underway to secure Tanzania’s compliance with international health regulations and obligations to the World Health Organization “to protect Tanzanians as well as all people in the region.” Tanzania’s government said Saturday there is no confirmed case of Ebola in the East African nation. No confirmed Ebola case has ever been recorded there. WHO in a statement last week noted a rumor regarding a death in Tanzania from an unknown illness and said it was sending a technical team to investigate “as a matter of urgency.” According to an internal WHO document seen by The Associated Press, the patient, a 34-year-old woman, died on Sept. 8 and was buried that day. It was not clear where she died. The document says the victim most recently was a student in central Uganda, where she visited health facilities on a research mission, before returning to Tanzania on Aug. 22. No case of Ebola has been reported in Uganda’s central region. “This mysterious disease has to be investigated and samples have to be tested. We couldn’t rule out any of the viral hemorrhagic fevers and the investigation will continue,” Dr. Yonas Woldemariam, the WHO representative in Uganda, said Monday. The Ebola outbreak in eastern Congo, which was declared over a year ago, has killed nearly 2,000 people. Health workers have been challenged by community mistrust and insecurity caused by years of rebel attacks. Cases of Ebola patients crossing borders during this outbreak have been rare. In June, a family of Congolese with sick family members crossed into Uganda via a bush path. Two died of Ebola inside Uganda. And in August, a Congolese girl tested positive for Ebola and later died in Uganda after traveling from Congo. ___ Follow Africa news at https://twitter.com/AP_Africa

Ex Output:
US urges transparency in Ebola-like death in Tanzania.


Ex Input:
The story mentioned that the cost of this drug treatment was several thousand dollars a month and that this was higher than the costs of other treatments. It would have been better to provide a more concrete estimate of costs (several thousand – does this mean 2,3 or 6 thousand?). The story might have included some information about additional costs that would be encountered with the comparison treatment such as the cost of intraveneous infusions, testing to  evaluate side-effects, and other connected costs. The story did a good job reporting the data comparing patient survival with Iressa as compared to individuals treated with IV chemotherapy. The story skimmed over the side effects; reducing the frequency of bothersome or life threatening side effects would seem to be an advantage. The story mentioned quality of life factors that appear to be better with Iressa but did not  quantify the benefit observed. Borderline satisfactory. The story listed the common side effects of the treatment though it failed to indicate the frequency with which these were seen. In addition, rather than than merely listing these, the story could have included some information about the severity of the side effects (i.e. bothersome vs. fatal). The story provided information about the size of the study conducted, the nature of the patients that were enrolled, and that the drug company that markets the drug funded the study. The study was designed as a non-inferiority survival trial to compare this medication with docotaxel, a chemotherapy treatment often used in individuals who have lung cancer and have had platinum based treatment but who are experiencing a return of their cancer. (While the story did provide information about the survival outcomes, it also included information comparing side effects.) The story ended with a comment from one of the interviewed clinicians about quality of life being better with Iressa. The story should have been clearer about the predetermined endpoint of the study (longevity) and should not have ended with less data driven information. The story did not engage in overt disease mongering. However the headline does not hint that the trial is not about first-line cancer treatment, rather just patients who have been treated previously with a platinum-based chemotherapy. The story included quotes from two individuals identified as not being connected with the study reported upon but with relevant expertise. The story provided information about two treatment options for individuals who have recurrence of a previously treated lung cancer. It did not provide information about the natural history of not undergoing additional treatment for this condition which is necessary for evaluating the relative merit of the two treatments discussed. The story did not mention radiation and surgery which are both options for some limited cancers. The story mentions that the medication Iressa (gefitinib) is sold in the United States but that its availability in Europe is limited. The story presented the use of Iressa as a treatment of individuals with lung cancer who had previously been treated with a platinum-based regimen as though it was a novel application. However – this drug was approved by the FDA in 2003 for this purpose. While the results of study reported on are interesting, the story did not provide the reader with a realistic picture of about the novelty of this product. Does not appear to rely on a press release.

Ex Output:
Pill as good as chemo on lung cancer, but costlier


Ex Input:
Thirteen years ago, the Advisory Committee on Immunization Practices recommended hepatitis A shots for all U.S. children at age 1. On Thursday, the panel said the shots should be given to older children who weren’t vaccinated earlier, including 14- to 18-year-olds who turned 1 before the recommendation was made. The panel also recommended the shots for every person with HIV. About 1.1 million Americans are estimated to have HIV, the virus that causes AIDS. People with HIV tend to develop more severe hepatitis A illnesses. U.S. hepatitis A infections and deaths have risen in the last two years, spurred by outbreaks among the homeless and drug users.

Ex Output:

Health panel: Millions of US kids should get hepatitis shot.